Abhinav Parikh1, Mathangi Gopalakrishnan2, Ahad Azeem3, Anastasia Booth4, Dina El-Metwally4. 1. University of Maryland Medical Center, Baltimore, MD, USA. abhinavparikh@gmail.com. 2. Center for Translational Medicine, School of Pharmacy, University of Maryland, Baltimore, MD, USA. 3. Long Island Jewish Forrest Hill Hospital, Forrest Hill, NY, 11375, USA. 4. University of Maryland Medical Center, Baltimore, MD, USA.
Abstract
OBJECTIVE: To determine if racial differences are associated with Neonatal Opioid Withdrawal Syndrome (NOWS) severity. STUDY DESIGN: A 10-year (2008-2017) retrospective cohort of infants ≥35 weeks gestation with prenatal exposure to opioids was included. The primary measure was the need for pharmacotherapy. Multivariable logistic regression and propensity score analysis were performed. RESULTS: Among 345 infants with NOWS, 111 (32%) were black infants with 70% of them requiring pharmacotherapy as compared with 84% of white infants. Upon adjusting for significant covariates (methadone, benzodiazepine use, and gestational age), black infants were 57% less likely than whites to require pharmacotherapy (Odds ratio: 0.43, 95%CI: 0.22-0.80, p = 0.009). Similar results were observed with propensity score analysis. CONCLUSIONS: Significant racial disparity observed may be secondary to genetic variations in opioid pharmacogenomics and/or extrinsic factors. Large-scale studies are warranted to include race in predictive models for early pharmacological intervention.
OBJECTIVE: To determine if racial differences are associated with Neonatal Opioid Withdrawal Syndrome (NOWS) severity. STUDY DESIGN: A 10-year (2008-2017) retrospective cohort of infants ≥35 weeks gestation with prenatal exposure to opioids was included. The primary measure was the need for pharmacotherapy. Multivariable logistic regression and propensity score analysis were performed. RESULTS: Among 345 infants with NOWS, 111 (32%) were black infants with 70% of them requiring pharmacotherapy as compared with 84% of white infants. Upon adjusting for significant covariates (methadone, benzodiazepine use, and gestational age), black infants were 57% less likely than whites to require pharmacotherapy (Odds ratio: 0.43, 95%CI: 0.22-0.80, p = 0.009). Similar results were observed with propensity score analysis. CONCLUSIONS: Significant racial disparity observed may be secondary to genetic variations in opioid pharmacogenomics and/or extrinsic factors. Large-scale studies are warranted to include race in predictive models for early pharmacological intervention.
Authors: Mary Peeler; Munish Gupta; Patrice Melvin; Allison S Bryant; Hafsatou Diop; Ronald Iverson; Katherine Callaghan; Elisha M Wachman; Rachana Singh; Mary Houghton; Shelly F Greenfield; Davida M Schiff Journal: Am J Public Health Date: 2020-10-15 Impact factor: 9.308
Authors: Massroor Pourcyrous; Mohamad T Elabiad; Divya Rana; Kan P Gaston; Linda DeBaer; Ramasubbareddy Dhanireddy Journal: Pediatr Res Date: 2020-11-19 Impact factor: 3.756
Authors: Shawana Bibi; Nathan Gaddis; Eric O Johnson; Barry M Lester; Walter Kraft; Rachana Singh; Norma Terrin; Susan Adeniyi-Jones; Jonathan M Davis Journal: Pediatr Res Date: 2022-08-16 Impact factor: 3.953
Authors: Stephanie L Merhar; Songthip Ounpraseuth; Lori A Devlin; Brenda B Poindexter; Leslie W Young; Sean D Berkey; Moira Crowley; Adam J Czynski; Autumn S Kiefer; Bonny L Whalen; Abhik Das; Janell F Fuller; Rosemary D Higgins; Vaishali Thombre; Barry M Lester; P Brian Smith; Sarah Newman; Pablo J Sánchez; M Cody Smith; Alan E Simon Journal: Pediatrics Date: 2021-03 Impact factor: 7.124
Authors: Rebecca R S Clark; Rachel French; Scott Lorch; Kathleen O'Rourke; Kathleen E Fitzpatrick Rosenbaum; Eileen T Lake Journal: Hosp Pediatr Date: 2021-07-06